Literature DB >> 18347040

Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates.

Laura E Via1, P Ling Lin, Sonja M Ray, Jose Carrillo, Shannon Sedberry Allen, Seok Yong Eum, Kimberly Taylor, Edwin Klein, Ujjini Manjunatha, Jacqueline Gonzales, Eun Gae Lee, Seung Kyu Park, James A Raleigh, Sang Nae Cho, David N McMurray, JoAnne L Flynn, Clifton E Barry.   

Abstract

Understanding the physical characteristics of the local microenvironment in which Mycobacterium tuberculosis resides is an important goal that may allow the targeting of metabolic processes to shorten drug regimens. Pimonidazole hydrochloride (Hypoxyprobe) is an imaging agent that is bioreductively activated only under hypoxic conditions in mammalian tissue. We employed this probe to evaluate the oxygen tension in tuberculous granulomas in four animal models of disease: mouse, guinea pig, rabbit, and nonhuman primate. Following infusion of pimonidazole into animals with established infections, lung tissues from the guinea pig, rabbit, and nonhuman primate showed discrete areas of pimonidazole adduct formation surrounding necrotic and caseous regions of pulmonary granulomas by immunohistochemical staining. This labeling could be substantially reduced by housing the animal under an atmosphere of 95% O(2). Direct measurement of tissue oxygen partial pressure by surgical insertion of a fiber optic oxygen probe into granulomas in the lungs of living infected rabbits demonstrated that even small (3-mm) pulmonary lesions were severely hypoxic (1.6 +/- 0.7 mm Hg). Finally, metronidazole, which has potent bactericidal activity in vitro only under low-oxygen culture conditions, was highly effective at reducing total-lung bacterial burdens in infected rabbits. Thus, three independent lines of evidence support the hypothesis that hypoxic microenvironments are an important feature of some lesions in these animal models of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347040      PMCID: PMC2423064          DOI: 10.1128/IAI.01515-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Metronidazole therapy in mice infected with tuberculosis.

Authors:  J V Brooks; S K Furney; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Enumeration of viable tubercle bacilli from the organs of nonimmunized and immunized mice.

Authors:  J L SEVER; G P YOUMANS
Journal:  Am Rev Tuberc       Date:  1957-10

3.  The treated pulmonary lesion and its tubercle bacillus. I. Pathology and pathogenesis.

Authors:  W E LORING; H M VANDIVIERE
Journal:  Am J Med Sci       Date:  1956-07       Impact factor: 2.378

4.  Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function.

Authors:  R Long; B Maycher; A Dhar; J Manfreda; E Hershfield; N Anthonisen
Journal:  Chest       Date:  1998-04       Impact factor: 9.410

5.  Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.

Authors:  Hyun J Shim; Yu C Kim; Joo H Lee; Jong W Kwon; Won B Kim; Yoon G Kim; So H Kim; Myung G Lee
Journal:  Biopharm Drug Dispos       Date:  2005-10       Impact factor: 1.627

6.  Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.

Authors:  J A Raleigh; D P Calkins-Adams; L H Rinker; C A Ballenger; M C Weissler; W C Fowler; D B Novotny; M A Varia
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

7.  Enhancement of oral absorption of metronidazole suspension in humans.

Authors:  N M Idkaidek; N M Najib
Journal:  Eur J Pharm Biopharm       Date:  2000-09       Impact factor: 5.571

8.  Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy.

Authors:  M I Voskuil; K C Visconti; G K Schoolnik
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

9.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more
  312 in total

1.  Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.

Authors:  Kathleen England; Helena I M Boshoff; Kriti Arora; Danielle Weiner; Emmanuel Dayao; Daniel Schimel; Laura E Via; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

2.  The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs.

Authors:  Lee G Klinkenberg; Jong-Hee Lee; William R Bishai; Petros C Karakousis
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

3.  Systems biology approaches to understanding mycobacterial survival mechanisms.

Authors:  Helena I M Boshoff; Desmond S Lun
Journal:  Drug Discov Today Dis Mech       Date:  2010

4.  Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry.

Authors:  M Lisa Manier; Michelle L Reyzer; Anne Goh; Veronique Dartois; Laura E Via; Clifton E Barry; Richard M Caprioli
Journal:  J Am Soc Mass Spectrom       Date:  2011-05-13       Impact factor: 3.109

5.  An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Hsin-Pin Ho Liang; Danielle Weiner; Jacqueline Gonzales; Laura E Via; Véronique Dartois
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

6.  Characterization of 3-ketosteroid 9{alpha}-hydroxylase, a Rieske oxygenase in the cholesterol degradation pathway of Mycobacterium tuberculosis.

Authors:  Jenna K Capyk; Igor D'Angelo; Natalie C Strynadka; Lindsay D Eltis
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

7.  Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.

Authors:  Noton K Dutta; Peter B Illei; Sanjay K Jain; Petros C Karakousis
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

8.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

Review 9.  Insights into the cellular responses to hypoxia in filamentous fungi.

Authors:  Falk Hillmann; Elena Shekhova; Olaf Kniemeyer
Journal:  Curr Genet       Date:  2015-04-25       Impact factor: 3.886

10.  Mycobacterium tuberculosis ftsZ expression and minimal promoter activity.

Authors:  Manjot Kiran; Erin Maloney; Hava Lofton; Ashwini Chauhan; Rasmus Jensen; Renata Dziedzic; Murty Madiraju; Malini Rajagopalan
Journal:  Tuberculosis (Edinb)       Date:  2009-12       Impact factor: 3.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.